Financial
FY2025 revenue £223.9m (+22.2%); operating margin -69.4%; net loss £145.2m.
No debt; £302.8m cash.
Oxford Nanopore Technologies
HQ United Kingdom · Europe
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Weak
Customer rating
No reviews yet
Financial health
Band: WeakListed: ONT.L
FY2025 revenue £223.9m (+22.2%); operating margin -69.4%; net loss £145.2m.
No debt; £302.8m cash.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | £223.9m | +22.2% | -£155.3m | -£145.2m | Oxford Nanopore Technologies |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Aug 2025: Oxford Nanopore announced that co-founder and CEO Gordon Sanghera will step down by the end of 2026, with the board running a formal search for a successor.
Cyber & information governance
Oct 2025: CISA advisory ICSMA-25-294-01 disclosed three vulnerabilities in Oxford Nanopore's MinKNOW sequencing software (two rated high), fixed in versions after 24.11. CISA reported no known public exploitation. NHS DSPT status not yet checked.
Regulatory & clinical safety
No product recalls, safety notices or clinical safety actions involving Oxford Nanopore Technologies found in HSH's search of the last 24 months.
Contract performance
No new notable contract awards, terminations or customer disputes involving Oxford Nanopore found in HSH's search of the last 24 months. Its pathogen surveillance partnership with the UK Government, NHS England and Genomics England (announced Nov 2024) was due to start in 2025.
Competitors
No competitors linked yet.